Guidance for IRBs, Clinical Investigators, and Sponsors

IRB Responsibilities for Reviewing the Qualifications of Investigators, Adequacy of Research Sites, and the Determination of Whether an IND/IDE is Needed

U.S. Department of Health and Human Services
Food and Drug Administration
Office of Good Clinical Practice (OGCP)
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)
Center for Devices and Radiological Health (CDRH)

August 2013
Procedural
Guidance for IRBs, Clinical Investigators, and Sponsors

IRB Responsibilities for Reviewing the Qualifications of Investigators, Adequacy of Research Sites, and the Determination of Whether an IND/IDE is Needed

Additional copies are available from:
Office of Communications
Division of Drug Information, WO51, Room 2201
Center for Drug Evaluation and Research
Food and Drug Administration
10903 New Hampshire Ave., Silver Spring, MD 20993
Phone: 301-796-3400; Fax: 301-847-8714
druginfo@fda.hhs.gov


and/or
Office of Communication, Outreach and Development, HFM-40
Center for Biologics Evaluation and Research
Food and Drug Administration
1401 Rockville Pike, Rockville, MD 20852-1448
(Tel) 800-835-4709 or 301-827-1800

and/or
Office of Communication, Education and Radiological Programs
Division of Small Manufacturers Assistance, WO66-4613
Center for Devices and Radiological Health
Food and Drug Administration
10903 New Hampshire Ave., Silver Spring, MD 20993
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/default.htm
Email: dsmica@cdrh.fda.gov; Fax: 301.847.8149
(Tel) Manufacturers Assistance: 800.638.2041 or 301.796.7100
(Tel) International Staff Phone: 301.827.3993

U.S. Department of Health and Human Services
Food and Drug Administration
Office of Good Clinical Practice
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)
Center for Devices and Radiological Health (CDRH)
August 2013
Procedural
## TABLE OF CONTENTS

I. INTRODUCTION ............................................................................................................. 1

II. BACKGROUND ............................................................................................................... 2

III. DISCUSSION .................................................................................................................... 2

1. Must an IRB review the qualifications of clinical investigators who conduct FDA-regulated research? ................................................................. 2

2. Is any information publicly available from FDA about a clinical investigator’s inspectional history? ................................................................. 4

3. Must an IRB review the adequacy of the research site? ......................................................... 4

4. What are the IRB’s responsibilities with respect to verifying the determination of whether an IND or IDE is required for an FDA-regulated investigation? ........................................................................ 5
I. INTRODUCTION

All of the parties who conduct or have oversight responsibilities for biomedical research—sponsors, clinical investigators, and institutional review boards (IRBs)—have responsibility for ensuring that the research complies with applicable laws and regulations and that risks to subjects are minimized. Although selection of clinical investigators and research sites, and determining if an investigational new drug application (IND) or investigational device exemption (IDE) is required are viewed primarily as sponsor responsibilities, FDA is issuing this guidance to clarify IRBs' responsibilities related to these activities and to encourage all parties to work together in order to protect the rights and welfare of study subjects.

FDA’s guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in agency guidances means that something is suggested or recommended, but not required.

To enhance protection of human subjects and reduce regulatory burden, the Department of Health and Human Services (HHS) Office for Human Research Protections (OHRP) and FDA have been actively working to harmonize the agencies’ regulatory requirements and guidance for human subject research. This guidance document was developed as a part of these efforts and in consultation with OHRP.

---

1 This guidance was prepared by the Office of Good Clinical Practice (OGCP) in the Office of the Commissioner, with input from the Center for Drug Evaluation and Research (CDER), the Center for Biologics Evaluation and Research (CBER), the Center for Devices and Radiological Health (CDRH), and the Office of Regulatory Affairs (ORA).
II. BACKGROUND

Many of the recommendations in this guidance have appeared in other FDA guidance documents or have been communicated to IRBs who have contacted the agency directly about these issues. FDA has also provided instructions to its field investigators on the types of records that should be reviewed during an IRB inspection to determine whether the IRB performed an evaluation of an investigator's qualifications, assessed the adequacy of a site, and questioned whether an IND or IDE is necessary. FDA has compiled the recommendations from these various sources into this guidance to ensure that all IRBs have access to it. In addition, FDA provides guidance on how IRBs may efficiently fulfill these important responsibilities.

The recommendations in this guidance are applicable to any IRB, independent or affiliated with an institution, whether serving as a local IRB or as the central IRB for other IRBs or institutions participating in a centralized review process for multi-site studies. The recommendations are general in order to provide IRBs with necessary flexibility in developing agreements for cooperative research as described in 21 CFR 56.114. As discussed in Guidance for Industry - Using a Centralized IRB Review Process in Multicenter Clinical Trials, FDA recommends that IRBs and institutions participating in a centralized review process agree on how to divide and carry out these responsibilities, and that such agreements be in writing to help ensure that the rights and welfare of study subjects are protected.

III. DISCUSSION

1. Must an IRB review the qualifications of clinical investigators who conduct FDA-regulated research?

Yes. Although FDA's regulations place responsibility on the sponsor to select clinical investigators who are "qualified by training and experience as appropriate experts" to investigate the test article, IRBs also have a role in reviewing an investigator's qualifications. The regulations at 21 CFR 56.107(a) require that an IRB "...be able to ascertain the acceptability of the proposed research in terms of institutional commitments and regulations, applicable law, and standards of professional conduct and practice..." In addition, the regulations at 21 CFR 56.111 require that an IRB determine that the proposed research satisfies the criteria for approval, including that "...risks to subjects are

---

2. ICH E6 Good Clinical Practice: Consolidated Guidance, 3.1.3 and 4.1.1
5. 21 CFR 312.53(a); see also 21 CFR 812.43(a).
6. See 21 CFR 56.102(g), (h), and (j) for definitions of IRB, investigator, and sponsor, respectively; http://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/ucm155713.htm.
in order to fulfill these responsibilities, the IRB needs information about the qualifications of the investigator(s) to conduct and supervise the proposed research. Depending upon the nature and risks of the proposed research and the relationship between the IRB and the investigator or the institution where the proposed research is being conducted, this may be relatively simple and straightforward or it may entail a more involved assessment.

In many cases, the IRB may have previous experience with an investigator or institution that would allow the IRB to readily determine that the clinical investigator is appropriately qualified to conduct and supervise the proposed research. In other cases, the IRB may need additional information; however, the IRB should be able to obtain a statement confirming the investigator’s qualifications from an administrator of the institution. For example, for proposed research to be conducted at a hospital where only credentialed hospital staff may conduct research, the IRB may be able to rely on another office at the institution (e.g., the credentialing office, the clinical investigator’s medical department) for information about the clinical investigator’s qualifications. For proposed research to be conducted by a university faculty member (e.g., at an affiliated hospital or clinic), the IRB may be able to obtain a statement regarding the investigator’s qualifications from the chair of the investigator’s department.

On the other hand, if the reviewing IRB has no knowledge of either the clinical investigator or the institution (e.g., the IRB is not affiliated with the institution where the research will be conducted; the IRB has no previous experience with the investigator), the IRB would likely need to take additional steps to evaluate the investigator’s qualifications. Such steps may include, as appropriate, reviewing the curriculum vitae of the investigator, subinvestigators, and other necessary study staff, verifying professional associations and medical licensure, or reviewing relevant publications and the investigator's training in good clinical practice.

The IRB may also need to assess the investigator’s training and experience specifically related to the proposed study, particularly if the proposed research involves higher risks, vulnerable subjects, or novel technologies. For such proposed research, the IRB’s determination that the investigator is qualified may need to include a review of the investigator’s previous specific experience as demonstrated by recent presentations or publications, and prior clinical experience with the test article or study-related procedures. In addition, the IRB should pay particular attention to an investigator’s qualifications to conduct a study submitted for approval to the IRB if the study involves one or more of the following:

- a sponsor-investigator, 7

7 FDA’s regulations (21 CFR 312.53(a) and 21 CFR 812.43(a)) require that a sponsor select clinical investigators who are "qualified by training and experience" to investigate the test article. In a sponsor-investigator (S-I) clinical trial, the S-I assumes the responsibilities of both the sponsor and the investigator (see 21 CFR 312.3(b) and 21 CFR 812.3(o)); therefore, there is no independent assessment of the clinical investigator’s qualifications by the study sponsor. In this case, the IRB’s review of the investigator’s qualifications is particularly important to the determination that the risks to subjects are minimized and reasonable in relation to anticipated benefits, if any, to subjects.
Contains Nonbinding Recommendations

- a study that is outside of the investigator's area of expertise; or
- any study design features or other characteristic(s) that may significantly increase potential risks to subjects.

If any concerns remain, the IRB may also elect to observe, or have a third party observe, the consent process and the research (21 CFR 56.109(f)).

Appropriately trained IRB support staff may assist in obtaining and assessing information about an investigator's qualifications. FDA recommends that the IRB's written procedures describe the IRB's process for evaluating the investigator's qualifications to conduct and supervise the study.

2. Is any information publicly available from FDA about a clinical investigator’s inspectional history?

Yes. IRBs may check the lists posted on FDA’s website to determine whether a clinical investigator has been the subject of an inspection by the agency and the results of such inspections (e.g., Warning Letters). FDA also posts on its website a listing of all investigators who have been notified of the initiation of a disqualification proceeding or have been disqualified. FDA recommends that IRBs routinely check FDA’s Inspections, Compliance, Enforcement, and Criminal Investigations website for information related to clinical investigator inspections, Warning Letters, disqualification proceedings, and debarments.

3. Must an IRB review the adequacy of the research site?

Yes. FDA’s regulations require that before an IRB can approve research covered by the regulations, the IRB must "...be able to ascertain the acceptability of the proposed research in terms of institutional commitments and regulations, applicable law, and standards of professional conduct and practice..." The regulations also require that each IRB have sufficient information to determine that the proposed research satisfies the criteria for approval.

---

8 Lists of investigators who have been inspected by FDA for CDER are posted at: [http://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/ComplianceEnforcement/default.htm](http://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/ComplianceEnforcement/default.htm); for CBER: [http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/ComplianceActivities/ucm165743.htm](http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/ComplianceActivities/ucm165743.htm). Investigators who conducted a device study from 2009 to present are included in the Inspection Classification Database maintained by FDA’s Office of Regulatory Affairs at: [http://www.accessdata.fda.gov/scripts/inspsearch](http://www.accessdata.fda.gov/scripts/inspsearch).

9 See the agency’s Electronic Reading Room, including Warning Letters ([http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/default.htm](http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/default.htm)).


11 See [http://www.fda.gov/ICECI/default.htm](http://www.fda.gov/ICECI/default.htm).

12 21 CFR 56.107(a).

13 21 CFR 56.111(a).
In the great majority of instances, an IRB will be familiar with the research site or institution at which the clinical investigator has proposed to conduct the research; in such cases, additional assessment of a site's adequacy will probably not be necessary (for example, if the research is to be conducted at the IRB's affiliated institution). In other cases, the IRB may need additional information to assess the site where the proposed research will take place to ensure it can adequately execute the protocol requirements. Depending upon the nature and risks of the proposed research and the IRB's prior knowledge of or relationship to the institution or other site at which the research will take place, this may be relatively simple and straightforward or it may entail a more involved assessment.

For example, if a proposed clinical investigation involves administration of medical procedures by qualified healthcare providers using medical equipment, the IRB should be prepared to assess the adequacy of the facility’s staff and equipment, including the availability of emergency or specialized care, should the need arise. If the proposed research site is part of a major medical institution, the IRB may be able to simply note that fact. If, however, the IRB is unfamiliar with the proposed investigational site (e.g., research facility, hospital, physician's office, dental clinic), the IRB may need to confirm whether the site is appropriately staffed and equipped to conduct the proposed research. The IRB should be able to obtain a statement from an appropriate person or persons at the research site or institution stating that the facilities are adequate. Alternatively, the IRB could ask that the investigator provide a description of the facility where the research will take place, including its staffing and resources relevant to the research under review.

Appropriately trained IRB support staff may assist in obtaining and assessing information about the adequacy of the research site. FDA recommends that the IRB's written procedures describe the IRB's process for carrying out these evaluations.

4. What are the IRB’s responsibilities with respect to verifying the determination of whether an IND or IDE is required for an FDA-regulated investigation?

In general, the IRB should ask the investigator if he/she considered whether an IND or IDE is required and the basis for that determination. The IRB's specific responsibilities may vary, however, depending on the product that is the subject of the study, as discussed below.

**Drug and Biologics Studies.** FDA regulations require sponsors\(^\text{14}\) and sponsor-investigators (of individual investigator-initiated studies) to determine whether an IND is required for a particular study.\(^\text{15}\) The sponsor should be able to determine whether the IND regulations apply to a planned clinical investigation as required under 21 CFR

---

\(^{14}\) See 21 CFR 312.3(b), definition of "sponsor-investigator." In this section, when "sponsor" is used, the term includes "sponsor-investigator."

\(^{15}\) See 21 CFR 312.2, 312.20, 312.50, and 320.31(c). Studies that are exempt from the IND requirements are required, however, to comply with 21 CFR Part 50 (Protection of Human Subjects) and Part 56 (Institutional Review Boards).
312.2(a). If a sponsor is uncertain whether an IND is required, we recommend that the sponsor contact the appropriate review division (i.e., for the therapeutic area being studied) in the appropriate FDA Center for advice (21 CFR 312.2(e)). FDA issued for public comment, Draft Guidance for Industry: Investigational New Drug Applications (INDs) — Determining Whether Human Research Studies Can Be Conducted Without an IND.\(^6\) When finalized, the guidance will represent FDA’s current thinking on this topic.

When reviewing a proposed study, IRBs should ask the clinical investigator whether the sponsor determined that an IND is or is not required and the basis for the determination. If the sponsor has determined that an IND is not required, the IRB may request that the investigator provide a copy of any available supporting documentation (e.g., letter from the sponsor or FDA, other basis for that determination). If during its initial review of a study, the IRB questions whether an IND is required, but is unable to resolve this issue, the IRB should follow its procedures for resolving controverted issues (e.g., notifying the clinical investigator in writing of the IRB’s concerns\(^7\) and delaying approval of the study until the matter is resolved).

Organizational charts listing the review divisions for the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) and their phone numbers are available on FDA’s website.\(^8\) If the relevant review division is not known, the sponsor may contact CDER or CBER directly:

CDER: Office of Communications, Division of Drug Information
        Center for Drug Evaluation and Research
        Food and Drug Administration
        10001 New Hampshire Avenue, 4th Floor
        Silver Spring, MD 20993
        (Tel) 301-796-3400

CBER: Office of Communication, Outreach and Development\(^9\)
       Center for Biologics Evaluation and Research
       Food and Drug Administration
       1401 Rockville Pike, Suite 200N
       Rockville, MD 20852-1448
       (Tel) 800-835-4709 or 301-827-1800

**Device Studies.** For studies involving an investigational device, the sponsor\(^10\) is responsible for determining whether submission of an IDE application to FDA is required


\(^7\) 21 CFR 56.109(e)

\(^8\) CDER: [http://www.fda.gov/AboutFDA/CentersOffices/OrganizationCharts/ucm135674.htm](http://www.fda.gov/AboutFDA/CentersOffices/OrganizationCharts/ucm135674.htm);

CBER: [http://www.fda.gov/AboutFDA/CentersOffices/OrganizationCharts/ucm135943.htm](http://www.fda.gov/AboutFDA/CentersOffices/OrganizationCharts/ucm135943.htm).

\(^9\) [http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CBER/ucm106001.htm](http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CBER/ucm106001.htm).
before a study may proceed.\textsuperscript{21} The IDE regulations (21 CFR 812) describe three types of device studies: significant risk (SR), nonsignificant risk (NSR), and exempt studies.\textsuperscript{22} SR device studies must have an IDE application approved by FDA and have IRB approval before they proceed, and they must follow all of the IDE requirements.\textsuperscript{23} NSR device studies must follow the abbreviated IDE requirements at 21 CFR 812.2(b), including informed consent and IRB review, and do not require submission of an IDE application to FDA.

The sponsor is responsible for making the initial risk determination, SR or NSR, and presenting it to the IRB.\textsuperscript{24} If the sponsor has determined that a device study is NSR, the IRB must review the sponsor’s determination.\textsuperscript{25} If the IRB disagrees with the sponsor’s NSR assessment and decides the study is SR, the IRB must inform the clinical investigator and, where appropriate, the sponsor.\textsuperscript{26} The IRB should also document its SR/NSR determination in the IRB meeting minutes.

FDA is available to assist sponsors, investigators, and IRBs in making these determinations. For information on how to request such assistance, please see the guidance \textit{Procedures for Handling Inquiries Regarding the Need for an Investigational Device Exemptions Application for Research Involving Medical Devices}.\textsuperscript{27} Sponsors, clinical investigators, and IRBs who need assistance in making a risk determination for a medical device may also contact:

\begin{center}
IDE Staff
Office of Device Evaluation
Center for Devices and Radiological Health
Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002
(Tel) 301-796-5640
\end{center}

Based on the information provided, FDA will determine if a device study is SR, NSR, or exempt from the IDE requirements found in 21 CFR Part 812. If FDA makes the SR, NSR, or exempt determination for a study, the agency's determination is final. Additional information may be found in the \textit{Information Sheet Guidance for IRBs},

\begin{flushright}
\textsuperscript{20} See 21 CFR 812.3(n) and 812.3(o); in this section, when "sponsor" is used, the term includes "sponsor-investigator."
\textsuperscript{21} 21 CFR 812.2(b)(1)(ii).
\textsuperscript{22} With the exception of 21 CFR 812.119, exempt studies are not subject to the IDE regulations. 21 CFR 812.2(c). Exempt studies are required to comply with 21 CFR Part 50 (Protection of Human Subjects) and Part 56 (Institutional Review Boards).
\textsuperscript{23} 21 CFR 812.20(a)(1) and (2).
\textsuperscript{24} 21 CFR 812.2(b)(1)(ii).
\textsuperscript{25} Ibid.
\textsuperscript{26} 21 CFR 812.66.
\textsuperscript{27} \url{http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm126598.htm}.
\end{flushright}
Contains Nonbinding Recommendations

Clinical Investigators, and Sponsors - Significant Risk and Nonsignificant Risk Medical Device Studies.\textsuperscript{28}

FDA recommends that the IRB have written procedures that explain how the IRB makes an SR/NSR determination.